Novavax, Inc. (NVAX)
After hours:
| Previous Close | 11.40 |
| Open | 11.45 |
| Bid | 11.03 x 700 |
| Ask | 12.44 x 900 |
| Day's Range | 11.13 - 12.48 |
| 52 Week Range | 3.53 - 23.86 |
| Volume | |
| Avg. Volume | 9,689,330 |
| Market Cap | 1.982B |
| Beta (5Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Yahoo Finance Video
FDA approves Novavax's updated COVID-19 vaccine
The US Food and Drug Administration (FDA) has given Novavax (NVAX) emergency use authorization to update its COVID-19 vaccine for patients 12 years and older. Josh Lipton and Madison Mills monitor Novavax's upward stock reaction to this news. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
- Associated Press Finance
US clears updated COVID shots from Novavax, adding a 3rd fall vaccine option
U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc. Already, Pfizer and Moderna are shipping shots modified to better match more recent strains of the ever-evolving coronavirus. Friday, the Food and Drug Administration gave the OK to the updated Novavax formula, too — and those shots are open to anyone 12 and older.
- Fortune
New COVID vaccines are here. What to know about the latest shots as summer surge continues
Citing skyrocketing COVID spread, the FDA announced in late August that it had approved Pfizer’s Comirnaty and Moderna’s Spikevax vaccines early.
